This is consistent with a recent multiethnic study consisted of 5724 participants free of cardiovascular disease followed for 10 years.[9] In that study, the associations of FGF21 with neither eGFR decline nor UACR progression were detected in the longitudinal analysis, although FGF21 was independently associated with decreased eGFR in the cross-sectional part of the study.[9] This may be because the decline in eGFR in relatively healthy people is slow, and circulating FGF21 has many influencing factors. Here, FGF21 is linked to cardiovascular disorder.